An official website of the United States government
Skip to Content

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Biometric Research Program

 

Last Updated:

Predictive Biomarkers in Phase II/III Clinical Trials

Stratified Design with Prospective Analysis Plan and Binary Endpoint

Randomized trial comparing new treatment (T) to control (C) includes both classifier positive and classifier negative patients. Presumes availability of binary classifier for biomarker predictive of benefit for new treatment.


Choose one analysis plan:

Analysis plan A: Determine sample size for overall test comparing T to C for all randomized patients at reduced two-sided level alpha. If overall test is not significant, then test T vs C in classifier positive subset using (.05-alpha) significance threshold.




Analysis plan B: Determine sample size for comparing T to C in classifier positive subset at two-sided .05 level. If that is significant at .05 level, then evaluate classifier negative subset at two-sided .05 level.



Analysis plan C: First test for interaction between size of treatment effect and subset (classifier + or classifier -). If interaction is non-significant, just compare treatments overall at two-sided significance level .05. Otherwise, compare treatments within subsets at two-sided .05 level.